본문 바로가기
KERD
논문KCI 등재

Outcome and Sequelae of Autoimmune Encephalitis

Kathryn A. Kvam|Jean-Paul Stahl|Felicia C. Chow|Ariane Soldatos|Pierre Tattevin|James Sejvar|Alexandra Mailles
대한신경과학회 (Korean Neurological Association)|2024.01|Journal of Clinical Neurology|제20권 제1호|pp. 3-22|DOI 10.3988/jcn.2023.0242

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

patient-reported outcomeoutcomescognitive impairmentautoimmune encephalitis

초록

Autoimmune etiologies are a common cause for encephalitis. The clinical syndromes consistent with autoimmune encephalitis are both distinct and increasingly recognized, but less is known about persisting sequelae or outcomes. We searched PubMed for reports on outcomes after autoimmune encephalitis. Studies assessing validated, quantitative outcomes were included. We performed a narrative review of the published literature of outcomes after autoimmune encephalitis. We found 146 studies that produced outcomes data. The mortality rates were 6%–19% and the relapse risks were 10%–62%. Most patients achieved a good outcome based on a score on the modified Rankin Scale (mRS) of ≤2. Forty-nine studies evaluated outcomes beyond mRS; these studies investigated cognitive outcome, psychiatric sequelae, neurological deficits, global function, and quality-of-life/patient-reported outcomes using various tools at varying time points after the index hospital discharge. These more-detailed assessments revealed that most patients had persistent impairments, with frequent deficits in cognitive function, especially memory and attention. Depression and anxiety were also common. Many of these sequelae continued to improve over months or even years after the acute illness. While we found that lasting impairments were common among survivors of autoimmune encephalitis, additional research is needed to better understand the nature and impact of these sequelae. Standardized evaluation protocols are needed to improve the ability to compare outcomes across studies, guide rehabilitation strategies, and inform outcomes of interest in treatment trials as the field advances.

Abstract

Autoimmune etiologies are a common cause for encephalitis. The clinical syndromes consistent with autoimmune encephalitis are both distinct and increasingly recognized, but less is known about persisting sequelae or outcomes. We searched PubMed for reports on outcomes after autoimmune encephalitis. Studies assessing validated, quantitative outcomes were included. We performed a narrative review of the published literature of outcomes after autoimmune encephalitis. We found 146 studies that produced outcomes data. The mortality rates were 6%–19% and the relapse risks were 10%–62%. Most patients achieved a good outcome based on a score on the modified Rankin Scale (mRS) of ≤2. Forty-nine studies evaluated outcomes beyond mRS; these studies investigated cognitive outcome, psychiatric sequelae, neurological deficits, global function, and quality-of-life/patient-reported outcomes using various tools at varying time points after the index hospital discharge. These more-detailed assessments revealed that most patients had persistent impairments, with frequent deficits in cognitive function, especially memory and attention. Depression and anxiety were also common. Many of these sequelae continued to improve over months or even years after the acute illness. While we found that lasting impairments were common among survivors of autoimmune encephalitis, additional research is needed to better understand the nature and impact of these sequelae. Standardized evaluation protocols are needed to improve the ability to compare outcomes across studies, guide rehabilitation strategies, and inform outcomes of interest in treatment trials as the field advances.

참고문헌 (82)

  1. Dalmau J, "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma", Ann Neurol, 61, pp.25~36 (2007)
  2. Graus F, "A clinical approach to diagnosis of autoimmune encephalitis", Lancet Neurol, 15, pp.391~404 (2016)
  3. Harutyunyan G, "Risk factors for intensive care unit admission in patients with autoimmune encephalitis", Front Immunol, 8, pp.835~ (2017)
  4. Abboud H, "Autoimmune encephalitis : proposed best practice recommendations for diagnosis and acute management", J Neurol Neurosurg Psychiatry, 92, pp.757~768 (2021)
  5. Dinoto A, "Bortezomib in anti-N-methyl-D-aspartate-receptor(NMDA-R)encephalitis : a systematic review", J Neuroimmunol, 356, pp.577586~ (2021)
  6. Lee WJ, "Tocilizumab in autoimmune encephalitis refractory to rituximab : an institutional cohort study", Neurotherapeutics, 13, pp.824~832 (2016)
  7. Lim JA, "New feasible treatment for refractory autoimmune encephalitis : low-dose interleukin-2", J Neuroimmunol, 299, pp.107~111 (2016)
  8. Wong KH, "The ExTINGUISH trial : a phase-2B randomized placebo-controlled trial of inebilizumab in anti-NMDA receptor encephalitis", Neurology, 99(23 Supplement 2), pp.S39~S40 (2022)
  9. Day G, "The ExTINGUISH trial : a phase-2B randomized placebo-controlled trial of inebilizumab in anti-NMDA receptor encephalitis(P5-1. 004)", Neurology, 98(18 supplement), pp.1651~ (2022)
  10. Broadley J, "Prognosticating autoimmune encephalitis : a systematic review", J Autoimmun, 96, pp.24~34 (2019)
  11. Nosadini M, "Use and safety of immunotherapeutic management of N-methyl-Daspartate receptor antibody encephalitis : a meta-analysis", JAMA Neurol, 78, pp.1333~1344 (2021)
  12. Tooren HVD, "How should we define a ‘good’ outcome from encephalitis? A systematic review of the range of outcome measures used in the long-term follow-up of patients with encephalitis", Clin Med (Lond), 22, pp.145~148 (2022)
  13. Rankin J, "Cerebral vascular accidents in patients over the age of 60. II. Prognosis", Scott Med J, 2, pp.200~215 (1957)
  14. Julayanont P, "The montreal cognitive assessment—basic : a screening tool for mild cognitive impairment in illiterate and low-educated elderly adults", J Am Geriatr Soc, 63, pp.2550~2554 (2015)
  15. Gong X, "Long-term functional outcomes and relapse of anti-NMDA receptor encephalitis : a cohort study in Western China", Neurol Neuroimmunol Neuroinflamm, 8, pp.e958~ (2021)
  16. Heine J, "Long-term cognitive outcome in anti-N-methyl-D-aspartate receptor encephalitis", Ann Neurol, 90, pp.949~961 (2021)
  17. Guasp M, "Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis : a prospective cohort study and comparison with patients with schizophrenia spectrum disorders", Lancet Neurol, 21, pp.899~910 (2022)
  18. Finke C, "Structural hippocampal damage following anti-N-methyl-D-aspartate receptor encephalitis", Biol Psychiatry, 79, pp.727~734 (2016)
  19. Phillips OR, "Superficial white matter damage in anti-NMDA receptor encephalitis", J Neurol Neurosurg Psychiatry, 89, pp.518~525 (2018)
  20. McKeon GL, "Cognitive and social functioning deficits after anti-N-methyl-D-aspartate receptor encephalitis : an exploratory case series", J Int Neuropsychol Soc, 22, pp.828~838 (2016)
  21. Finke C, "Cognitive deficits following anti-NMDA receptor encephalitis", J Neurol Neurosurg Psychiatry, 83, pp.195~198 (2012)
  22. Wang W, "Anti-NMDA receptor encephalitis : clinical characteristics, predictors of outcome and the knowledge gap in southwest China", Eur J Neurol, 23, pp.621~629 (2016)
  23. Wu H, "Catatonia in adult anti-NMDAR encephalitis : an observational cohort study", BMC Psychiatry, 23, pp.94~ (2023)
  24. Gordon-Lipkin E, "Comparative outcomes in children and adults with anti-N-methyl-D-aspartate(anti-NMDA)receptor encephalitis", J Child Neurol, 32, pp.930~935 (2017)
  25. Yeshokumar A, "Younger age at onset is associated with worse long-term behavioral outcomes in anti-NMDA receptor encephalitis", Neurol Neuroimmunol Neuroinflamm, 9, pp.e200013~ (2022)
  26. Blum RA, "Assessment of long-term psychosocial outcomes in anti-NMDA receptor encephalitis", Epilepsy Behav, 108, pp.107088~ (2020)
  27. Lee WJ, "Disease progression and brain atrophy in NMDAR encephalitis : associated factor & clinical implication", Ann Clin Transl Neurol, 9, pp.912~924 (2022)
  28. Thompson J, "The importance of early immunotherapy in patients with faciobrachial dystonic seizures", Brain, 141, pp.348~356 (2018)
  29. Hang HL, "Clinical characteristics of cognitive impairment and 1-year outcome in patients with anti-LGI1antibody encephalitis", Front Neurol, 11, pp.852~ (2020)
  30. Szots M, "Global brain atrophy and metabolic dysfunction in LGI1 encephalitis : a prospective multimodal MRI study", J Neurol Sci, 376, pp.159~165 (2017)
  31. Alkabie S, "Prolonged corticosteroids without maintenance immunotherapy for treatment of anti-LGI1 encephalitis : analysis of outcomes and relapse rate", Neurol Neuroimmunol Neuroinflamm, 10, pp.e200115~ (2023)
  32. Binks SNM, "Residual fatigue and cognitive deficits in patients after leucine-rich glioma-inactivated 1 antibody encephalitis", JAMA Neurol, 78, pp.617~619 (2021)
  33. Finke C, "Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies", JAMA Neurol, 74, pp.50~59 (2017)
  34. Loane C, "Hippocampal network abnormalities explain amnesia after VGKCC-Ab related autoimmune limbic encephalitis", J Neurol Neurosurg Psychiatry, 90, pp.965~974 (2019)
  35. Galioto R, "Cognitive outcomes in anti-LGI-1 encephalitis", J Int Neuropsychol Soc, 29, pp.541~550 (2023)
  36. Frisch C, "Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis", Eur J Neurol, 20, pp.1297~1304 (2013)
  37. Butler CR, "Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex", J Neurol Neurosurg Psychiatry, 85, pp.387~391 (2014)
  38. Rodriguez A, "LGI1 antibody encephalitis : acute treatment comparisons and outcome", J Neurol Neurosurg Psychiatry, 93, pp.309~315 (2022)
  39. Malter MP, "Outcome of limbic encephalitis with VGKCcomplex antibodies : relation to antigenic specificity", J Neurol, 261, pp.1695~1705 (2014)
  40. Bettcher BM, "More than memory impairment in voltage-gated potassium channel complex encephalopathy", Eur J Neurol, 21, pp.1301~1310 (2014)
  41. van Sonderen A, "Anti-LGI1 encephalitis : clinical syndrome and longterm follow-up", Neurology, 87, pp.1449~1456 (2016)
  42. Thieben MJ, "Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody", Neurology, 62, pp.1177~1182 (2004)
  43. Sola-Valls N, "Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis", Neurol Neuroimmunol Neuroinflamm, 7, pp.e652~ (2019)
  44. Wagner J, "Distinct white matter integrity in glutamic acid decarboxylase and voltage-gated potassium channel-complex antibodyassociated limbic encephalitis", Epilepsia, 57, pp.475~483 (2016)
  45. Chen W, "Neurofunctional outcomes in patients with anti-leucine-rich glioma inactivated 1 encephalitis", Acta Neurol Scand, 144, pp.632~639 (2021)
  46. Benoit J, "Early-stage contactin-associated protein-like 2 limbic encephalitis : clues for diagnosis", Neurol Neuroimmunol Neuroinflamm, 10, pp.e200041~ (2022)
  47. Höftberger R, "Encephalitis and GABAB receptor antibodies : novel findings in a new case series of 20 patients", Neurology, 81, pp.1500~1506 (2013)
  48. Ji C, "The long-term outcome of neuropsychological function is favorable in patients with non-malignancy related anti-GABABR encephalitis : a case series", BMC Neurol, 21, pp.87~ (2021)
  49. Chen W, "A prognostic analysis of the outcomes in patients with anti-γ-aminobutyric acid B receptor encephalitis", Front Immunol, 13, pp.847494~ (2022)
  50. Lin J, "Long-term cognitive and neuropsychiatric outcomes of anti-GABABR encephalitis patients : a prospective study", J Neuroimmunol, 351, pp.577471~ (2021)
  51. Höftberger R, "Encephalitis and AMPA receptor antibodies : novel findings in a case series of 22 patients", Neurology, 84, pp.2403~2412 (2015)
  52. Spatola M, "Investigations in GABAA receptor antibody-associated encephalitis", Neurology, 88, pp.1012~1020 (2017)
  53. Hara M, "DPPX antibody-associated encephalitis : main syndrome and antibody effects", Neurology, 88, pp.1340~1348 (2017)
  54. Budhram A, "Clinical spectrum of high-titre GAD65 antibodies", J Neurol Neurosurg Psychiatry, 92, pp.645~654 (2021)
  55. Carvajal-González A, "Glycine receptor antibodies in PERM and related syndromes : characteristics, clinical features and outcomes", Brain, 137(Pt 8), pp.2178~2192 (2014)
  56. Dalmau J, "Clinical analysis of anti-Ma2-associated encephalitis", Brain, 127(Pt 8), pp.1831~1844 (2004)
  57. Wang J, "Clinical and imaging features of patients with encephalitic symptoms and myelin oligodendrocyte glycoprotein antibodies", Front Immunol, 12, pp.722404~ (2021)
  58. Lee WJ, "MOG antibody-associated encephalitis in adult : clinical phenotypes and outcomes", J Neurol Neurosurg Psychiatry, 94, pp.102~112 (2023)
  59. Gaig C, "Clinical manifestations of the anti-IgLON5 disease", Neurology, 88, pp.1736~1743 (2017)
  60. Flanagan EP, "Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy : analysis of 102 patients", Ann Neurol, 81, pp.298~309 (2017)
  61. Iorio R, "Clinical and immunological characteristics of the spectrum of GFAP autoimmunity : a case series of 22 patients", J Neurol Neurosurg Psychiatry, 89, pp.138~146 (2018)
  62. Dubey D, "Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11 encephalitis", JAMA Neurol, 77, pp.1420~1429 (2020)
  63. Lee WJ, "Seronegative autoimmune encephalitis : clinical characteristics and factors associated with outcomes", Brain, 145, pp.3509~3521 (2022)
  64. von Rhein B, "Suspected antibody negative autoimmune limbic encephalitis : outcome of immunotherapy", Acta Neurol Scand, 135, pp.134~141 (2017)
  65. Griffith S, "Psychometric deficits in autoimmune encephalitis : a retrospective study from the Australian Autoimmune Encephalitis Consortium", Eur J Neurol, 29, pp.2355~2366 (2022)
  66. Hébert J, "Long-term cognitive outcomes in patients with autoimmune encephalitis", Can J Neurol Sci, 45, pp.540~544 (2018)
  67. Dogan Onugoren M, "Immunoadsorption therapy in autoimmune encephalitides", Neurol Neuroimmunol Neuroinflamm, 3, pp.e207~ (2016)
  68. Abboud H, "Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults", J Neurol Sci, 434, pp.120124~ (2022)
  69. Griffith SP, "Characterizing cognitive function in patients with autoimmune encephalitis : an Australian prospective study", J Neurol (2023)[DOI]
  70. Yeshokumar AK, "Neurobehavioral outcomes in autoimmune encephalitis", J Neuroimmunol, 312, pp.8~14 (2017)
  71. Diaz-Arias LA, "Fatigue in survivors of autoimmune encephalitis", Neurol Neuroimmunol Neuroinflamm, 8, pp.e1064~ (2021)
  72. Du Y, "Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies", J Neuroinflammation, 19, pp.259~ (2022)
  73. Macher S, "Clinical scales in autoimmune encephalitis—A retrospective monocentric cohort study", Ann Clin Transl Neurol, 10, pp.1768~1775 (2023)
  74. Thakur KT, "Predictors of outcome in acute encephalitis", Neurology, 81, pp.793~800 (2013)
  75. Singh TD, "The spectrum of acute encephalitis : causes, management, and predictors of outcome", Neurology, 84, pp.359~366 (2015)
  76. Harris L, "Neuropsychological and psychiatric outcomes in encephalitis : a multicentre case-control study", PLoS One, 15, pp.e0230436~ (2020)
  77. Chen W, "Status epilepticus associated with acute encephalitis : long-term follow-up of functional and cognitive outcomes in 72 patients", Eur J Neurol, 25, pp.1228~1234 (2018)
  78. Kim T, "Changes in function and muscle strength of encephalitis survivors after inpatient rehabilitation", Ann Rehabil Med, 45, pp.422~430 (2021)
  79. Kvam KA, "Outcome and sequelae of infectious encephalitis in adult patients", J Clin Neurol, 20, pp.23~36 (2024)
  80. Lim JA, "Development of the clinical assessment scale in autoimmune encephalitis", Ann Neurol, 85, pp.352~358 (2019)
  81. Dubey D, "The spectrum of autoimmune encephalopathies", J Neuroimmunol, 287, pp.93~97 (2015)
  82. Thaler FS, "Rituximab treatment and long-term outcome of patients with autoimmune encephalitis : real-world evidence from the GENERATE registry", Neurol Neuroimmunol Neuroinflamm, 8, pp.e1088~ (2021)

관련 논문AI추천

Te Diagnosis and Treatment of Autoimmune EncephalitisEric Lancaster대한신경과학회 · Journal of Clinical Neurology2016 · 제12권 제1호Autoantibody Encephalitis: Presentation, Diagnosis, and ManagementEric Lancaster대한신경과학회 · Journal of Clinical Neurology2022 · 제18권 제4호AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines—A Systematic ReviewAbhishek Chowdhury, Abhishek Gohel, Aritra Chatterjee, Bhavesh Mohan Lal, Debjyoti Dhar, MM Samim, Naznin Parvin, Nibu Varghese, Rutul D. Shah, Sampurna Chowdhury, Shahyan Siddiqui, Sheetal Goyal, Treshita Dey, Vikram Singh대한신경과학회 · Journal of Clinical Neurology2022 · 제18권 제6호Clinical Features and Treatment Outcomes of Seronegative Pediatric Autoimmune Encephalitis강훈철, 김세희, 김흥동, 이상보, 이준수대한신경과학회 · Journal of Clinical Neurology2021 · 제17권 제2호Analysis of Risk Factors for a Poor Prognosis in Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Construction of a Prognostic Composite ScoreFeng Li, Gang Yu, Libo Zhu, Li Wang, Meng Ni, Yejia Mo, Yetao Luo대한신경과학회 · Journal of Clinical Neurology2020 · 제16권 제3호Brain Atrophy Can Predict the Severity and Prognosis of Anti-N-Methyl-D-Aspartate Receptor EncephalitisBingjun Zhang, Haiyan Li, Yanling Li, Yinyao Lin, Yongqiang Dai, Yuge Wang대한신경과학회 · Journal of Clinical Neurology2025 · 제21권 제5호

이 간행물의 다른 논문 (16건)

Advances in Idiopathic Inflammatory Myopathies Classification: Paving the Way for Personalized ManagementByung-Jo Kim, 박진우pp. 1-2Outcome and Sequelae of Infectious EncephalitisFelicia C. Chow, Jean-Paul Stahl, Kathryn A. Kvam, Alexandra Mailles, James Sejvar, Pierre Tattevin, Ariane Soldatospp. 23-36Abnormal Ocular Movement in the Early Stage of Multiple-System Atrophy With Predominant Parkinsonism Distinct From Parkinson’s DiseaseLuhua Wei, Jing Chen, Wei Sun, Lin Zhang, Yunchuang Sun, Hong Zhou, Yanyan Jiang, Xia Wang, Fan Li, Guiping Zhao, Zhaoxia Wangpp. 37-45Normative Values for Serum Neurofilament Light Chain in US AdultsThomas A. Beltranpp. 46-49Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy: A Multicenter Cohort Study in South KoreaYoung Nam Kwon, Sung-Min Kim, Ha Young Shin, Seok-Jin Choi, 홍윤호, So-Young Huh, Ilhan Yoo, Kyung-Seok Park, Jong-Gyu Baek, Hee-Jo Han, Jun-Soon Kim, Young Gi Min, 성정준, Seol-Hee Baekpp. 50-58
원문 보기